LTP001 / Novartis - LARVOL DELTA

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) (clinicaltrials.gov) - P1/2 | N=232 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) (clinicaltrials.gov) - P1/2 | N=232 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals

New P1/2 trial • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF (clinicaltrials.gov) - P2 | N=46 | Terminated | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Terminated; Sponsor Decision

Trial termination • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants (clinicaltrials.gov) - P2 | N=31 | Terminated | Sponsor: Novartis Pharmaceuticals | Completed ➔ Terminated; Sponsor Decision

Trial termination • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension (clinicaltrials.gov) - P2 | N=47 | Terminated | Sponsor: Novartis Pharmaceuticals | Completed ➔ Terminated; Sponsor Decision

Trial termination • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF (clinicaltrials.gov) - P2 | N=46 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Nov 2024 ➔ Aug 2024 | Trial primary completion date: Oct 2024 ➔ Jul 2024

Trial completion date • Trial primary completion date • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension (clinicaltrials.gov) - P2 | N=47 | Completed | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants (clinicaltrials.gov) - P2 | N=31 | Completed | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Completed

Trial completion • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF (clinicaltrials.gov) - P2 | N=46 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting | N=94 ➔ 46

Enrollment change • Enrollment closed • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF (clinicaltrials.gov) - P2 | N=94 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Apr 2026 ➔ Nov 2024 | Trial primary completion date: Apr 2026 ➔ Nov 2024

Trial completion date • Trial primary completion date • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Sep 2025 ➔ Apr 2024 | Trial primary completion date: Sep 2025 ➔ Apr 2024

Trial completion date • Trial primary completion date • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension (clinicaltrials.gov) - P2 | N=47 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF (clinicaltrials.gov) - P2 | N=94 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: May 2025 ➔ Jun 2026 | Trial primary completion date: May 2025 ➔ May 2026

Trial completion date • Trial primary completion date • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF (clinicaltrials.gov) - P2 | N=94 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Feb 2025 ➔ May 2025 | Trial primary completion date: Feb 2025 ➔ May 2025

Trial completion date • Trial primary completion date • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants (clinicaltrials.gov) - P2 | N=40 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals

New P2 trial • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF (clinicaltrials.gov) - P2 | N=94 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF (clinicaltrials.gov) - P2 | N=94 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: May 2025 ➔ Feb 2025 | Initiation date: Mar 2023 ➔ Oct 2022 | Trial primary completion date: May 2025 ➔ Jan 2025

Trial completion date • Trial initiation date • Trial primary completion date • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF (clinicaltrials.gov) - P2 | N=94 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Feb 2025 ➔ May 2025 | Initiation date: Oct 2022 ➔ Mar 2023 | Trial primary completion date: Jan 2025 ➔ May 2025

Trial completion date • Trial initiation date • Trial primary completion date • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF (clinicaltrials.gov) - P2 | N=94 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals

New P2 trial • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension (clinicaltrials.gov) - P2 | N=44 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension (clinicaltrials.gov) - P2; N=44; Not yet recruiting; Sponsor: Novartis Pharmaceuticals; Trial completion date: Jul 2023 ➔ Mar 2024; Trial primary completion date: Jul 2023 ➔ Mar 2024

Clinical • Trial completion date • Trial primary completion date • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension (clinicaltrials.gov) - P2; N=44; Not yet recruiting; Sponsor: Novartis Pharmaceuticals

Clinical • New P2 trial • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases